Hepion Pharmaceuticals Inc (HEPA)

[Fress]

CRV431 in NASH Phase 2a Preliminary Conclusions

Reduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjects.

CRV431 concentration predicts reductions in serum alanine transaminase.

Trial Simulations suggest greater expected efficacy at 150 mg and 225 mg dose levels.

Bioinformatics with AI-POWR? reveal significant interactions with collagen regulating genes.

Confirmation of these effects will be fully evaluated using the 225 mg cohort and the final genomic,

lipidomic, and biomarker data for a full simulation of the Phase 2b Trial.


No approved drugs for Nash 14 Billion market over the next few years.


$HEPA